{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:56:46Z","timestamp":1790841406003,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20242BAB25421"],"award-info":[{"award-number":["20242BAB25421"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.intimp.2026.116481","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:31:29Z","timestamp":1773084689000},"page":"116481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of a low-dose nivolumab regimen (240\u00a0mg) as neoadjuvant immunochemotherapy in Chinese patients with resectable non-small cell lung cancer: a prospective single-arm, exploratory study"],"prefix":"10.1016","volume":"176","author":[{"given":"Zhengdong","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuchen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.116481_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung cancer 2020: epidemiology, etiology, and prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.intimp.2026.116481_bb0010","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.lungcan.2004.07.997","article-title":"Impact of low-dose CT on lung cancer screening","volume":"45","author":"Diederich","year":"2004","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2026.116481_bb0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun."},{"issue":"4","key":"10.1016\/j.intimp.2026.116481_bb0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non\u2013small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"suppl_4","key":"10.1016\/j.intimp.2026.116481_bb0025","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.intimp.2026.116481_bb0030","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.2009.27.6204","article-title":"Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non\u2013small-cell lung cancer","volume":"28","author":"Felip","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116481_bb0035","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/JTO.0b013e3181b9ecca","article-title":"Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials","volume":"4","author":"Lim","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.116481_bb0040","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/S0169-5002(01)00361-0","article-title":"The role of chemotherapy in early stage of non-small cell lung cancer","volume":"34","author":"Souquet","year":"2001","journal-title":"Lung Cancer"},{"issue":"21","key":"10.1016\/j.intimp.2026.116481_bb0045","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group","volume":"26","author":"Pignon","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.intimp.2026.116481_bb0050","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.intimp.2026.116481_bb0055","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti\u2013programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non\u2013small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"10066","key":"10.1016\/j.intimp.2026.116481_bb0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.intimp.2026.116481_bb0065","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New England J. Med."},{"issue":"26","key":"10.1016\/j.intimp.2026.116481_bb0070","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.21.00276","article-title":"SAKK 16\/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non\u2013small-cell lung cancer\u2014a multicenter single-arm phase II trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116481_bb0075","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.intimp.2026.116481_bb0080","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"New England J. Med."},{"issue":"11","key":"10.1016\/j.intimp.2026.116481_bb0085","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.116481_bb0090","doi-asserted-by":"crossref","unstructured":"Ulas, E., et al., Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. ESMO Open, 2021. 6(5): p. 100244.","DOI":"10.1016\/j.esmoop.2021.100244"},{"issue":"21","key":"10.1016\/j.intimp.2026.116481_bb0095","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.intimp.2026.116481_bb0100","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"issue":"17","key":"10.1016\/j.intimp.2026.116481_bb0105","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of nivolumab in previously treated advanced non\u2013small-cell lung cancer: results from the CA209-003 study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116481_bb0110","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial","volume":"14","author":"Wu","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"10481","key":"10.1016\/j.intimp.2026.116481_bb0115","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","author":"Ng","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.intimp.2026.116481_bb0120","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jtho.2022.06.010","article-title":"Safety implications of switching pembrolizumab dosage from 200 mg every 3 weeks to 400 mg every 6 weeks in patients with advanced NSCLC","volume":"17","author":"Higashiyama","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"10.1016\/j.intimp.2026.116481_bb0125","first-page":"2495","article-title":"New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1). Gan to kagaku ryoho","volume":"36","author":"Watanabe","year":"2009","journal-title":"Cancer & chemotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2026.116481_bb0130","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116481_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102040","article-title":"Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816","volume":"8","author":"Wang","year":"2023","journal-title":"ESMO open"},{"issue":"6","key":"10.1016\/j.intimp.2026.116481_bb0140","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.intimp.2026.116481_bb0145","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.21.02660","article-title":"Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non\u2013small-cell lung cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.intimp.2026.116481_bb0150","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2217\/fon-2019-0031","article-title":"Nivolumab plus ipilimumab in non-small-cell lung cancer","volume":"15","author":"Reck","year":"2019","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116481_bb0155","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1245\/s10434-023-14356-9","article-title":"Neoadjuvant and adjuvant pembrolizumab for the treatment of early-stage resectable non-small cell lung cancer an editorial regarding the interim data analysis of the KEYNOTE-671 phase III trial of neoadjuvant and adjuvant pembrolizumab","volume":"31","author":"Ruck","year":"2024","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116481_bb0160","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.116481_bb0165","series-title":"Two Cycles Versus Three Cycles of Neoadjuvant Sintilimab plus Platinum-Doublet Chemotherapy in Patients with Resectable Non-small-Cell Lung cancer (neoSCORE): A Randomized, Single Center, Two-Arm Phase II Trial","author":"Qiu","year":"2022"},{"issue":"6","key":"10.1016\/j.intimp.2026.116481_bb0170","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.21037\/tlcr-2020-63","article-title":"Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer","volume":"9","author":"Liang","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.intimp.2026.116481_bb0175","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2023.02.001","article-title":"Utility of 18F-FDG PET\/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer","volume":"178","author":"Zhuang","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2026.116481_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.994917","article-title":"Comprehensive 18F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: a pilot study","volume":"13","author":"Cui","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116481_bb0185","doi-asserted-by":"crossref","first-page":"8564","DOI":"10.1007\/s00330-023-09910-8","article-title":"Clinical utility of [18F] FDG PET\/CT in the assessment of mediastinal lymph node disease after neoadjuvant chemoimmunotherapy for non-small cell lung cancer","volume":"33","author":"Zhang","year":"2023","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.intimp.2026.116481_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107389","article-title":"The predictive value of 18F-FDG PET\/CT combined with inflammatory index for major pathological reactions in resectable NSCLC receiving neoadjuvant immunochemotherapy","volume":"186","author":"Yin","year":"2023","journal-title":"Lung Cancer"},{"issue":"10027","key":"10.1016\/j.intimp.2026.116481_bb0195","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2026.116481_bb0200","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.116481_bb0205","article-title":"Case report: an \u201cimmune-cold\u201d EGFR mutant NSCLC with strong PD-L1 expression shows resistance to chemo-immunotherapy","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116481_bb0210","doi-asserted-by":"crossref","unstructured":"Fricke, J., et al., Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: a case report. Medicine, 2020. 99(46): p. e22323.","DOI":"10.1097\/MD.0000000000022323"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926003255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926003255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:09:07Z","timestamp":1790838547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926003255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":42,"alternative-id":["S1567576926003255"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116481","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of a low-dose nivolumab regimen (240\u00a0mg) as neoadjuvant immunochemotherapy in Chinese patients with resectable non-small cell lung cancer: a prospective single-arm, exploratory study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116481"}}